We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
(+29%)
Cap. Flow
+$32.2M
Cap. Flow
% of AUM
1.94%
Top 10 Holdings %
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38
Avg Time Held Equity + Options
2.1
quarters
Top 10 Avg Time Held Equity + Options
2.8
quarters
Top 20 Avg Time Held Equity + Options
3
quarters
Avg Time Held Equity only
2.2
quarters
Top 10 Avg Time Held Equity only
2.9
quarters
Top 20 Avg Time Held Equity only
3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Ignyta, Inc.
RXDX
|
+$23.8M |
| 2 |
Viatris
VTRS
|
+$14.8M |
| 3 |
Eagle Pharmaceuticals, Inc.
EGRX
|
+$14.4M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$12.4M |
| 5 |
NEVRO CORP.
NVRO
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$19.4M |
| 2 |
bluebird bio
BLUE
|
+$16.3M |
| 3 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$12.1M |
| 4 |
uniQure
QURE
|
+$11.1M |
| 5 |
RLYP
RELYPSA INC COM
RLYP
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.96% |
| 2 | Miscellaneous | 17.3% |
| 3 | Consumer Staples | 0.52% |
| 4 | Financials | 0.09% |
| 5 | Technology | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
MGCD
101
DELISTED
MGC Diagnostics Corporation
MGCD
| $1.76M | 0.11% |
336,287
| – | – |
2013 Q2
8 quarters
|
|
|
ARIA
102
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $1.59M | 0.1% |
191,949
+150,000
| +358% | +$1.33M |
2015 Q1
1 quarter
|
|
103
Incyte
INCY
$22B
| $1.56M | 0.09% |
15,000
+5,000
| +50% | +$518K |
2015 Q1
1 quarter
|
|
104
SCYNEXIS
SCYX
$39.7M
| $1.54M | 0.09% |
+2,188
| New | +$1.57M |
2015 Q2
0 quarters
|
|
105
DELISTED
Sage Therapeutics
SAGE
| $1.46M | 0.09% |
20,000
-50,484
| -72% | -$3.25M |
2014 Q3
3 quarters
|
|
106
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $1.44M | 0.09% |
26,667
| – | – |
2015 Q1
1 quarter
|
|
|
EPZM
107
DELISTED
Epizyme, Inc
EPZM
| $1.44M | 0.09% |
+60,000
| New | +$1.15M |
2015 Q2
0 quarters
|
|
108
DELISTED
Avinger, Inc. Common Stock
AVGR
| $1.32M | 0.08% |
1
| – | – |
2015 Q1
1 quarter
|
|
|
TCON
109
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $1.29M | 0.08% |
500
| – | – |
2015 Q1
1 quarter
|
|
|
AET
110
DELISTED
Aetna Inc
AET
| $1.29M | 0.08% |
10,086
+7,500
| +290% | +$856K |
2014 Q2
4 quarters
|
|
|
GNVC
111
DELISTED
GenVec, Inc.
GNVC
| $1.26M | 0.08% |
61,584
| – | – |
2014 Q1
5 quarters
|
|
112
EyePoint Inc
EYPT
$265M
| $1.19M | 0.07% |
31,500
| – | – |
2014 Q4
2 quarters
|
|
113
DELISTED
Cogentix Medical, Inc.
CGNT
| $1.09M | 0.07% |
+673,257
| New | +$1.1M |
2015 Q2
0 quarters
|
|
114
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $1.03M | 0.06% |
+20,000
| New | +$1.06M |
2015 Q2
0 quarters
|
|
|
IMPR
115
DELISTED
IMPRIVATA, INC COM
IMPR
| $982K | 0.06% |
60,000
+10,000
| +20% | +$150K |
2015 Q1
1 quarter
|
|
|
STML
116
DELISTED
Stemline Therapeutics, Inc.
STML
| $933K | 0.06% |
79,245
| – | – |
2015 Q1
1 quarter
|
|
117
Neurogene
NGNE
$431M
| $902K | 0.05% |
6,500
| – | – |
2014 Q1
5 quarters
|
|
118
Stellantis
STLA
$12.9B
| $901K | 0.05% |
+95,090
| New | +$975K |
2015 Q2
0 quarters
|
|
119
Danaher
DHR
$157B
| $856K | 0.05% |
+14,878
| New | +$852K |
2015 Q2
0 quarters
|
|
120
Eocene Ltd. Ordinary Shares
EOCN
$3.39M
| $755K | 0.05% |
52
| – | – |
2014 Q1
5 quarters
|
|
121
Grace Therapeutics
GRCE
$41.9M
| $745K | 0.04% |
4,928
| – | – |
2013 Q3
7 quarters
|
|
|
DRNA
122
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $698K | 0.04% |
+50,000
| New | +$917K |
2015 Q2
0 quarters
|
|
|
ABMD
123
DELISTED
Abiomed Inc
ABMD
| $657K | 0.04% |
10,000
| – | – |
2015 Q1
1 quarter
|
|
|
TRIL
124
DELISTED
Trillium Therapeutics Inc.
TRIL
| $655K | 0.04% |
+30,000
| New | +$684K |
2015 Q2
0 quarters
|
|
|
HSTO
125
DELISTED
Histogen Inc. Common Stock
HSTO
| $515K | 0.03% |
+500
| New | +$586K |
2015 Q2
0 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2015 Portfolio in Review
As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Perceptive Advisors's Q2 2015 filing shows 55 new, 41 increased, 36 reduced and 38 closed positions. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M. The largest sale was Neurocrine Biosciences, an estimated $19.4M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Miscellaneous and Consumer Staples.
- Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
- Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
- Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
- Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
- Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
- Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
- Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.
Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.